Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 759 clinical trials
None
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

There is very limited data on the use of arsenic trioxide in newly diagnosed patients with acute promyelocytic leukemia. The use of arsenic trioxide was limited to relapsed patients mainly because of the superior efficacy of ATRA as primary therapy for newly diagnosed APML. Though the early study by Niu …

arsenic
tretinoin
remission
hepatic toxicity
  • 76 views
  • 07 Nov, 2020
  • 8 locations
None
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

The primary objective of this study is to determine the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary objective is to determine the response to treatment (based on bone marrow and peripheral blood findings). A tertiary objective is to determine the impact …

decitabine
platelet count
anemia
lenalidomide
myelomonocytic leukemia
  • 0 views
  • 14 Mar, 2021
  • 1 location
None
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

stem cell transplantation
high risk myelodysplastic syndrome
myelomonocytic leukemia
leukemia
cmml-2
  • 7 views
  • 25 Nov, 2021
  • 138 locations
None
Canakinumab and Anacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

decitabine
anemia
lenalidomide
hydroxyurea
myelomonocytic leukemia
  • 0 views
  • 25 Jan, 2021
None
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the …

decitabine
chemotherapy drugs
myelomonocytic leukemia
hematopoietic growth factors
growth factor
  • 0 views
  • 25 Nov, 2021
None
Inqovi Maintenance Therapy in Myeloid Neoplasms

This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. This research study involves the study drug Inqovi, which is a combination of the drugs decitabine …

decitabine
antifungal agents
myelomonocytic leukemia
hla-a
graft versus host disease
  • 0 views
  • 17 Oct, 2021
  • 1 location
None
Clinical Guidelines for APL Treatment

Therapeutic guidelines for treatment of patients with de novo APL to be used by every institution that wants to follow them. All patients who are reported may be retrospectively analyzed

tretinoin
methotrexate
idarubicin
  • 28 views
  • 29 Mar, 2021
  • 1 location
None
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis. The primary objectives of the study are: To evaluate the frequency of the different subtypes of MDS in childhood and …

chromosomal abnormality
myeloid leukemia
chromosome abnormality
myelodysplastic syndromes
leukemia
  • 8 views
  • 26 Jan, 2021
  • 1 location
None
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

hematopoietic growth factors
transplant conditioning
growth factor
fludarabine
cytarabine
  • 254 views
  • 26 Nov, 2021
  • 39 locations